ChabioTech Obtains Japanese Patent for 'Enhanced Umbilical Cord-Derived Adhesive Stem Cells'
[Asia Economy Reporter Kum Boryeong] Cha Biotech announced on the 15th that it has acquired a Japanese patent related to 'Improved Umbilical Cord-Derived Adherent Stem Cells, Their Manufacturing Method, and Their Use.'
Hot Picks Today
![Shocked While Looking for Jeonse... "A 30-Year-Old Apartment Costs 900 Million Won" Supply Halved in Northern Seoul [Real Estate AtoZ]](https://cwcontent.asiae.co.kr/asiaresize/93/2026092210331237896_1790040791.jpg)
Shocked While Looking for Jeonse... "A 30-Year-Old Apartment Costs 900 Million Won" Supply Halved in Northern Seoul [Real Estate AtoZ]
- "I Went for the Cheap Coffee, but Now I Feel Uneasy"... Major Coffee Franchises Cited for Violations One After Another
- "My Vicarious Satisfaction Every Night Gone: Sudden Deletion of Past Videos... Mukbang YouTubers Hit by Crackdown"
- A 30-Dollar Painting No One Bought Turns Out to Be a 250,000-Dollar 'Original' Thanks to a Signature
- "After Spending 170,000 Won on Hanwoo, This Is What I Got": Why Webtoon Artist Kim Gyusam Decided to Give Cash Instead
Cha Biotech stated, "The improved umbilical cord-derived adherent stem cells have anti-inflammatory effects, vascular regeneration effects, or nerve regeneration effects, and are usefully applied in pharmaceutical compositions or cell therapies for the treatment or prevention of various diseases." They added, "In the future, when conducting regenerative medicine business including clinical trials of cell therapies in Japan, we plan to utilize this to establish a technical foundation for new drug substances and manufacturing methods, and to secure a preemptive position through patent rights protection."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
